Evidence map›Paper›PMID 31828108›Full record

ArticleBioMed research international2019

A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.

Hong Ye, Shuming Qin, Ning Li, Min Lin, Yanmei Xu, Xiaomei Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. International journal of surgical pathology · 2023
    Review
  5. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hong YeDepartment of Pathology, Tai'an Central Hospital, Tai'an 271000, China.
Shuming QinDepartment of Pathology, Tai'an Central Hospital, Tai'an 271000, China.
Ning LiDepartment of Pathology, Tai'an Central Hospital, Tai'an 271000, China.
Min LinDepartment of Pathology, Tai'an Central Hospital, Tai'an 271000, China.
Yanmei XuDepartment of Pathology, Shanxian Central Hospital, Heze 274300, China.
Xiaomei LiDepartment of Pathology, Tai'an Central Hospital, Tai'an 271000, China.ORCID https://orcid.org/0000-0001-6505-3363
Taian City Central Hospital · CNXian Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xp11 translocation renal cell carcinoma (RCC), a member of the microphthalmia-associated transcription factor (MiTF) family, is a rare renal tumor characterized by different translocations involving the

Indexed as

AdultBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorCarcinoma, Renal CellChromosomes, Human, XFemaleHumansIn Situ Hybridization, FluorescenceMaleMediator ComplexMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalOncogene Proteins, FusionSequence Analysis, RNATomography, X-Ray ComputedBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorMED15 protein, humanMediator ComplexNeoplasm ProteinsOncogene Proteins, FusionTFE3 protein, human

Identifiers

PMID31828108
PMCPMC6881588
OpenAlexW2982952190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.